PedAM

Pediatric Disease Annotations & Medicines


	lymphoma, non-hodgkin

Disease ID	691
Disease	lymphoma, non-hodgkin
Synonym	[m]malignant lymphoma, non-hodgkin's type [m]malignant lymphoma, small cleaved cell, diffuse [m]malignant lymphoma, small cleaved cell, diffuse (morphologic abnormality) [m]non-hodgkin's lymphoma [x]non-hodgkin's lymphoma, unspecified type [x]non-hodgkin's lymphoma, unspecified type (disorder) diffuse non-hodgkin's small cleaved cell (diffuse) lymphoma diffuse small cleaved cell lymphoma diffuse small cleaved lymphoma diffuse small cleaved-cell lymphoma lymphoma small cleaved diffuse lymphoma, atypical diffuse small lymphoid lymphoma, non hodgkin lymphoma, non hodgkin's lymphoma, non hodgkins lymphoma, non-hodgkin [disease/finding] lymphoma, non-hodgkin's lymphoma, non-hodgkin, familial lymphoma, non-hodgkins lymphoma, nonhodgkin lymphoma, nonhodgkin's lymphoma, nonhodgkins lymphoma, small cleaved cell, diffuse lymphoma, small cleaved-cell, diffuse malignant lymphoma non hodgkins type malignant lymphoma, cleaved cell [obs] malignant lymphoma, non-hodgkin malignant lymphoma, non-hodgkin's malignant lymphoma, non-hodgkin's type malignant lymphoma, non-hodgkin's, nos malignant lymphoma, small cell, noncleaved, diffuse [obs] malignant lymphoma, small cleaved cell [obs] malignant lymphoma, small cleaved cell, diffuse -retired- malignant lymphoma, small cleaved cell, diffuse [obs] malignant lymphoma, undifferentiated cell type [obs] malignant lymphoma, undifferentiated cell, non-burkitt [obs] nhl nhl - non-hodgkin's lymphoma nhl, nos non hodgkin lymphoma non hodgkin's lymphoma non hodgkin's lymphoma (nhl) non hodgkins lymphoma non-hodgkin lymphoma non-hodgkin lymphoma (category) non-hodgkin lymphoma - category non-hodgkin lymphoma - category (morphologic abnormality) non-hodgkin lymphoma, no icd-o subtype non-hodgkin lymphoma, no icd-o subtype (morphologic abnormality) non-hodgkin lymphoma, no international classification of diseases for oncology subtype non-hodgkin lymphoma, no international classification of diseases for oncology subtype (morphologic abnormality) non-hodgkin lymphoma, nos non-hodgkin's lymphoma non-hodgkin's lymphoma (clinical) non-hodgkin's lymphoma (disorder) non-hodgkin's lymphoma (nhl) non-hodgkin's lymphoma - disorder non-hodgkin's lymphoma nos non-hodgkin's lymphoma, nos non-hodgkin`s lymphoma non-hodgkins lymphoma nonhodgkin lymphoma nonhodgkin's lymphoma nonhodgkins lymphoma small cleaved cell lymphoma, diffuse small cleaved lymphoma diffuse small cleaved-cell lymphoma, diffuse
Orphanet	ORPHANET:547
OMIM	OMIM:605027 OMIM:608833
DOID	DOID:0060060
MeSH	D008228
SNOMED-CT	SNOMEDCT_US_2016_09_01:118601006
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:95) C0024299 \| lymphoma \| 31 C0079731 \| b-cell non-hodgkin lymphoma \| 13 C0024299 \| lymphomas \| 11 C0042769 \| virus infection \| 6 C0024301 \| follicular lymphoma \| 6 C0079731 \| b-cell lymphoma \| 5 C0270612 \| leukoencephalopathy \| 4 C0079744 \| diffuse large b-cell lymphoma \| 4 C0023418 \| leukemia \| 4 C0023524 \| progressive multifocal leukoencephalopathy \| 4 C0027947 \| neutropenia \| 3 C0032285 \| pneumonia \| 3 C0003864 \| arthritis \| 2 C0019360 \| zoster \| 2 C0019158 \| hepatitis \| 2 C0042384 \| vasculitis \| 2 C0019163 \| hepatitis b \| 2 C0004623 \| bacterial infections \| 2 C0376545 \| hematologic malignancies \| 2 C0019360 \| herpes zoster \| 2 C0004623 \| bacterial infection \| 2 C0006413 \| burkitt lymphoma \| 2 C0021053 \| immune disease \| 2 C0007114 \| skin cancer \| 2 C0742472 \| cns lymphoma \| 2 C0019196 \| hepatitis c \| 2 C0023449 \| acute lymphocytic leukemia \| 1 C0010068 \| coronary artery disease \| 1 C0019618 \| histiocytosis \| 1 C0003872 \| psoriatic arthritis \| 1 C0021053 \| immune dysfunction \| 1 C0027726 \| nephrotic syndrome \| 1 C0007114 \| skin cancers \| 1 C0014038 \| encephalitis \| 1 C0002880 \| autoimmune hemolytic anemia \| 1 C0744421 \| immune complex glomerulonephritis \| 1 C0023443 \| hairy cell leukemia \| 1 C0021053 \| immune disorders \| 1 C0023290 \| visceral leishmaniasis \| 1 C0030807 \| pemphigus \| 1 C0007570 \| celiac disease \| 1 C0026764 \| myeloma \| 1 C0023448 \| lymphocytic leukemia \| 1 C0036220 \| kaposi's sarcoma \| 1 C0032285 \| pneumonitis \| 1 C0017658 \| glomerulonephritis \| 1 C0017665 \| membranous glomerulonephritis \| 1 C0023473 \| chronic myeloid leukemia \| 1 C0026764 \| multiple myeloma \| 1 C0021053 \| immune disorder \| 1 C0242647 \| malt lymphoma \| 1 C0043194 \| wiskott-aldrich syndrome \| 1 C0334634 \| mantle cell lymphoma \| 1 C0007115 \| thyroid cancer \| 1 C0026948 \| mycosis fungoides \| 1 C0010403 \| cryoglobulinemia \| 1 C0206083 \| central pontine myelinolysis \| 1 C0011603 \| dermatitis \| 1 C0019829 \| hodgkin lymphoma \| 1 C0025202 \| melanoma \| 1 C0152025 \| polyneuropathy \| 1 C0206062 \| interstitial lung disease \| 1 C0026848 \| muscle disorders \| 1 C1261473 \| sarcoma \| 1 C0032305 \| pneumocystis pneumonia \| 1 C0023281 \| leishmaniasis \| 1 C0023470 \| myeloid leukemia \| 1 C0019069 \| hemophilia \| 1 C1275081 \| cardiofaciocutaneous syndrome \| 1 C0007115 \| thyroid ca \| 1 C0038362 \| stomatitis \| 1 C0003873 \| rheumatoid arthritis \| 1 C0023418 \| leukaemia \| 1 C0007134 \| renal cell carcinoma \| 1 C0026946 \| mycosis \| 1 C0024314 \| lymphoproliferative disease \| 1 C0040034 \| thrombocytopenia \| 1 C0699893 \| nonmelanoma skin cancer \| 1 C0282193 \| iron overload \| 1 C0079731 \| b cell lymphoma \| 1 C0002871 \| anemia \| 1 C0002878 \| hemolytic anemia \| 1 C0009402 \| colorectal cancer \| 1 C0024115 \| lung disease \| 1 C0011608 \| dermatitis herpetiformis \| 1 C0023827 \| liposarcoma \| 1 C0740372 \| gastrointestinal lymphoma \| 1 C0007113 \| rectal cancer \| 1 C0376545 \| hematological malignancies \| 1 C0021933 \| intussusception \| 1 C0019348 \| herpes simplex \| 1 C0032305 \| pneumocystis jiroveci pneumonia \| 1 C0032305 \| pneumocystis \| 1 C0085669 \| acute leukemia \| 1 C0027708 \| wilms' tumor \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:23) HLA-DRB1 \| 3123 \| CTD_human TP53 \| 7157 \| CLINVAR BCL2 \| 596 \| CTD_human BCL6 \| 604 \| CTD_human EPHX1 \| 2052 \| CTD_human CSF2 \| 1437 \| CTD_human TYMS \| 7298 \| CTD_human CHEK2 \| 11200 \| CTD_human IFNA2 \| 3440 \| CTD_human MTHFR \| 4524 \| CTD_human BRAF \| 673 \| CLINVAR;UNIPROT CSF3 \| 1440 \| CTD_human RTEL1 \| 51750 \| OMIM CYP2E1 \| 1571 \| CTD_human SHMT1 \| 6470 \| CTD_human RAD54L \| 8438 \| CLINVAR;CTD_human CASP10 \| 843 \| CLINVAR;CTD_human;UNIPROT BHMT \| 635 \| CTD_human FPGS \| 2356 \| CTD_human TFRC \| 7037 \| CTD_human CBS \| 875 \| CTD_human PRF1 \| 5551 \| CLINVAR;CTD_human RAD54B \| 25788 \| CLINVAR
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:259) 64746 \| ACBD3 \| infer 6868 \| ADAM17 \| infer 128 \| ADH5 \| infer 154 \| ADRB2 \| infer 155 \| ADRB3 \| infer 196 \| AHR \| infer 10327 \| AKR1A1 \| infer 1645 \| AKR1C1 \| infer 8644 \| AKR1C3 \| infer 10840 \| ALDH1L1 \| infer 336 \| APOA2 \| infer 337 \| APOA4 \| infer 338 \| APOB \| infer 348 \| APOE \| infer 367 \| AR \| infer 285973 \| ATG9B \| infer 572 \| BAD \| infer 578 \| BAK1 \| infer 581 \| BAX \| infer 596 \| BCL2 \| infer 598 \| BCL2L1 \| infer 604 \| BCL6 \| infer 635 \| BHMT \| infer 638 \| BIK \| infer 641 \| BLM \| infer 672 \| BRCA1 \| infer 713 \| C1QB \| infer 714 \| C1QC \| infer 114905 \| C1QTNF7 \| infer 51279 \| C1RL \| infer 716 \| C1S \| infer 717 \| C2 \| infer 718 \| C3 \| infer 719 \| C3AR1 \| infer 720 \| C4A \| infer 722 \| C4BPA \| infer 725 \| C4BPB \| infer 727 \| C5 \| infer 728 \| C5AR1 \| infer 729 \| C6 \| infer 730 \| C7 \| infer 732 \| C8B \| infer 735 \| C9 \| infer 834 \| CASP1 \| infer 843 \| CASP10 \| infer 23581 \| CASP14 \| infer 835 \| CASP2 \| infer 836 \| CASP3 \| infer 837 \| CASP4 \| infer 838 \| CASP5 \| infer 839 \| CASP6 \| infer 840 \| CASP7 \| infer 841 \| CASP8 \| infer 9994 \| CASP8AP2 \| infer 842 \| CASP9 \| infer 875 \| CBS \| infer 6347 \| CCL2 \| infer 6352 \| CCL5 \| infer 6355 \| CCL8 \| infer 595 \| CCND1 \| infer 1232 \| CCR3 \| infer 940 \| CD28 \| infer 958 \| CD40 \| infer 4179 \| CD46 \| infer 1604 \| CD55 \| infer 966 \| CD59 \| infer 22918 \| CD93 \| infer 1019 \| CDK4 \| infer 1029 \| CDKN2A \| infer 1030 \| CDKN2B \| infer 1071 \| CETP \| infer 629 \| CFB \| infer 1675 \| CFD \| infer 3075 \| CFH \| infer 3078 \| CFHR1 \| infer 81494 \| CFHR5 \| infer 1147 \| CHUK \| infer 1191 \| CLU \| infer 1312 \| COMT \| infer 1378 \| CR1 \| infer 1380 \| CR2 \| infer 1493 \| CTLA4 \| infer 1524 \| CX3CR1 \| infer 7852 \| CXCR4 \| infer 1535 \| CYBA \| infer 1584 \| CYP11B1 \| infer 1585 \| CYP11B2 \| infer 1586 \| CYP17A1 \| infer 1588 \| CYP19A1 \| infer 1543 \| CYP1A1 \| infer 1544 \| CYP1A2 \| infer 1545 \| CYP1B1 \| infer 1589 \| CYP21A2 \| infer 1559 \| CYP2C9 \| infer 1571 \| CYP2E1 \| infer 1719 \| DHFR \| infer 1813 \| DRD2 \| infer 1814 \| DRD3 \| infer 1816 \| DRD5 \| infer 2052 \| EPHX1 \| infer 2053 \| EPHX2 \| infer 2068 \| ERCC2 \| infer 2073 \| ERCC5 \| infer 2099 \| ESR1 \| infer 2100 \| ESR2 \| infer 2208 \| FCER2 \| infer 2212 \| FCGR2A \| infer 2214 \| FCGR3A \| infer 2222 \| FDFT1 \| infer 2321 \| FLT1 \| infer 2356 \| FPGS \| infer 2688 \| GH1 \| infer 2690 \| GHR \| infer 51738 \| GHRL \| infer 2876 \| GPX1 \| infer 2879 \| GPX4 \| infer 2944 \| GSTM1 \| infer 2947 \| GSTM3 \| infer 2950 \| GSTP1 \| infer 2952 \| GSTT1 \| infer 3014 \| H2AFX \| infer 3105 \| HLA-A \| infer 3106 \| HLA-B \| infer 3107 \| HLA-C \| infer 3119 \| HLA-DQB1 \| infer 3123 \| HLA-DRB1 \| infer 3157 \| HMGCS1 \| infer 3158 \| HMGCS2 \| infer 3240 \| HP \| infer 3292 \| HSD17B1 \| infer 3294 \| HSD17B2 \| infer 3283 \| HSD3B1 \| infer 3284 \| HSD3B2 \| infer 3383 \| ICAM1 \| infer 29851 \| ICOS \| infer 3458 \| IFNG \| infer 3479 \| IGF1 \| infer 3480 \| IGF1R \| infer 3481 \| IGF2 \| infer 3482 \| IGF2R \| infer 3484 \| IGFBP1 \| infer 3486 \| IGFBP3 \| infer 3551 \| IKBKB \| infer 3586 \| IL10 \| infer 3603 \| IL16 \| infer 3565 \| IL4 \| infer 3566 \| IL4R \| infer 3689 \| ITGB2 \| infer 3952 \| LEP \| infer 3981 \| LIG4 \| infer 3990 \| LIPC \| infer 4023 \| LPL \| infer 4049 \| LTA \| infer 10747 \| MASP2 \| infer 4153 \| MBL2 \| infer 4157 \| MC1R \| infer 4286 \| MITF \| infer 4312 \| MMP1 \| infer 4313 \| MMP2 \| infer 4314 \| MMP3 \| infer 4318 \| MMP9 \| infer 4353 \| MPO \| infer 4436 \| MSH2 \| infer 4524 \| MTHFR \| infer 10588 \| MTHFS \| infer 4548 \| MTR \| infer 4552 \| MTRR \| infer 9 \| NAT1 \| infer 10 \| NAT2 \| infer 4683 \| NBN \| infer 4688 \| NCF2 \| infer 4689 \| NCF4 \| infer 8202 \| NCOA3 \| infer 4790 \| NFKB1 \| infer 4792 \| NFKBIA \| infer 4793 \| NFKBIB \| infer 64127 \| NOD2 \| infer 4842 \| NOS1 \| infer 4843 \| NOS2 \| infer 4846 \| NOS3 \| infer 4864 \| NPC1 \| infer 10577 \| NPC2 \| infer 4852 \| NPY \| infer 1728 \| NQO1 \| infer 7376 \| NR1H2 \| infer 10062 \| NR1H3 \| infer 2908 \| NR3C1 \| infer 4948 \| OCA2 \| infer 4968 \| OGG1 \| infer 56288 \| PARD3 \| infer 8505 \| PARG \| infer 142 \| PARP1 \| infer 23590 \| PDSS1 \| infer 5241 \| PGR \| infer 5443 \| POMC \| infer 5617 \| PRL \| infer 5618 \| PRLR \| infer 5742 \| PTGS1 \| infer 5743 \| PTGS2 \| infer 5770 \| PTPN1 \| infer 5879 \| RAC1 \| infer 5880 \| RAC2 \| infer 10111 \| RAD50 \| infer 5896 \| RAG1 \| infer 5966 \| REL \| infer 8737 \| RIPK1 \| infer 866 \| SERPINA6 \| infer 710 \| SERPING1 \| infer 6462 \| SHBG \| infer 6470 \| SHMT1 \| infer 6472 \| SHMT2 \| infer 23411 \| SIRT1 \| infer 9963 \| SLC23A1 \| infer 9962 \| SLC23A2 \| infer 6531 \| SLC6A3 \| infer 9021 \| SOCS3 \| infer 6647 \| SOD1 \| infer 6648 \| SOD2 \| infer 6649 \| SOD3 \| infer 6715 \| SRD5A1 \| infer 6770 \| STAR \| infer 83930 \| STARD3NL \| infer 6774 \| STAT3 \| infer 6778 \| STAT6 \| infer 7076 \| TIMP1 \| infer 7078 \| TIMP3 \| infer 7096 \| TLR1 \| infer 81793 \| TLR10 \| infer 7097 \| TLR2 \| infer 7099 \| TLR4 \| infer 10333 \| TLR6 \| infer 7124 \| TNF \| infer 7132 \| TNFRSF1A \| infer 7133 \| TNFRSF1B \| infer 944 \| TNFSF8 \| infer 8717 \| TRADD \| infer 7186 \| TRAF2 \| infer 7188 \| TRAF5 \| infer 222642 \| TSPO2 \| infer 7298 \| TYMS \| infer 7299 \| TYR \| infer 7412 \| VCAM1 \| infer 7421 \| VDR \| infer 7422 \| VEGFA \| infer 7486 \| WRN \| infer 7515 \| XRCC1 \| infer 7517 \| XRCC3 \| infer 847 \| CAT \| infer 4862 \| NPAS2 \| infer 5444 \| PON1 \| infer 3567 \| IL5 \| infer 3569 \| IL6 \| infer 5468 \| PPARG \| infer 3552 \| IL1A \| infer 3553 \| IL1B \| infer 3557 \| IL1RN \| infer 3558 \| IL2 \| infer 4609 \| MYC \| infer 6573 \| SLC19A1 \| infer
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	691
Disease	lymphoma, non-hodgkin
Integrated Phenotype	HPO \| Name(Total Integrated Phenotypes:1) HP:0002665 \| Lymphoma
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:66) HP:0002665 \| Lymphoma \| 32 HP:0002664 \| Neoplasia \| 15 HP:0012191 \| B-cell lymphoma \| 6 HP:0001909 \| Leukemia \| 5 HP:0002721 \| Immunodeficiency \| 5 HP:0002352 \| Leukoencephalopathy \| 4 HP:0002960 \| Autoimmune condition \| 4 HP:0002202 \| Pleural effusion \| 3 HP:0002090 \| Pneumonia \| 3 HP:0000718 \| Aggressive behaviour \| 3 HP:0001875 \| Neutropenia \| 3 HP:0030069 \| Primary central nervous system lymphoma \| 2 HP:0002633 \| Vasculitis \| 2 HP:0012115 \| Liver inflammation \| 2 HP:0030080 \| Burkitt lymphoma \| 2 HP:0002716 \| Lymph node hyperplasia \| 2 HP:0100778 \| Cryoglobulinemia \| 2 HP:0001369 \| Arthritis \| 2 HP:0000099 \| Glomerular nephritis \| 1 HP:0001890 \| Autoimmune hemolytic anemia \| 1 HP:0100727 \| Histiocytosis \| 1 HP:0008940 \| Generalized lymphadenopathy \| 1 HP:0002383 \| Encephalitis \| 1 HP:0030731 \| Carcinoma \| 1 HP:0100820 \| Glomerulopathy \| 1 HP:0100543 \| Cognitive deficits \| 1 HP:0100726 \| Kaposi's sarcoma \| 1 HP:0012054 \| Choroidal melanoma \| 1 HP:0002861 \| Melanoma \| 1 HP:0006530 \| Interstitial lung disease \| 1 HP:0009733 \| Glioma \| 1 HP:0002013 \| Emesis \| 1 HP:0001873 \| Low platelet count \| 1 HP:0012324 \| Myeloid leukemia \| 1 HP:0100242 \| Sarcoma \| 1 HP:0002576 \| Intussusception \| 1 HP:0002017 \| Nausea and vomiting \| 1 HP:0012034 \| Liposarcoma \| 1 HP:0002885 \| Medulloblastoma \| 1 HP:0009027 \| Foot drop \| 1 HP:0001878 \| Haemolytic anaemia \| 1 HP:0002018 \| Nausea \| 1 HP:0005200 \| Retroperitoneal fibrosis \| 1 HP:0006775 \| Multiple myeloma \| 1 HP:0001271 \| Polyneuropathy \| 1 HP:0012189 \| Hodgkin disease \| 1 HP:0001903 \| Anemia \| 1 HP:0001370 \| Rheumatoid arthritis \| 1 HP:0012190 \| T cell lymphoma \| 1 HP:0000100 \| Nephrosis \| 1 HP:0005506 \| Chronic myeloid leukemia \| 1 HP:0001677 \| Coronary artery disease \| 1 HP:0012378 \| Fatigue \| 1 HP:0010280 \| Stomatitis \| 1 HP:0005584 \| Renal cell carcinoma \| 1 HP:0002608 \| Celiac disease \| 1 HP:0001397 \| Hepatic steatosis \| 1 HP:0012578 \| Membranous glomerulonephritis \| 1 HP:0010310 \| Chylothorax \| 1 HP:0001824 \| Weight loss \| 1 HP:0002176 \| Spinal cord compression \| 1 HP:0002398 \| Anterior horn cell loss \| 1 HP:0002488 \| Acute leukemias \| 1 HP:0030159 \| Cervical polyp \| 1 HP:0001744 \| Splenomegaly \| 1 HP:0006721 \| Acute lymphocytic leukemia \| 1

Disease ID	691
Disease	lymphoma, non-hodgkin
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:12) C0042769 \| virus infection \| 6 C0032227 \| pleural effusion \| 3 C0746883 \| febrile neutropenia \| 3 C0021051 \| immunodeficiency \| 3 C0007114 \| skin cancer \| 2 C0037140 \| b virus infection \| 2 C0042384 \| vasculitis \| 2 C0008733 \| chylothorax \| 1 C0026848 \| muscle disorders \| 1 C0037926 \| spinal cord compression \| 1 C1112570 \| paraneoplastic pemphigus \| 1 C0152025 \| polyneuropathy \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:180)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs1041163	19533685	3596	IL13	umls:C0024305	BeFree	Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).	0.000814326	2009	VCAM1	1	100718269	T	C
rs1041163	19533685	7412	VCAM1	umls:C0024305	BeFree	Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).	0.002638474	2009	VCAM1	1	100718269	T	C
rs1042522	25203442	7157	TP53	umls:C0024305	BeFree	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.	0.132539865	2014	TP53	17	7676154	G	T,C
rs1042522	25203442	4194	MDM4	umls:C0024305	BeFree	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.	0.000271442	2014	TP53	17	7676154	G	T,C
rs104894176	NA	5551	PRF1	umls:C0024305	CLINVAR	NA	0.24	NA	PRF1	10	70598599	C	T
rs1048943	19899130	1543	CYP1A1	umls:C0024305	BeFree	Our data provide evidence that the GSTP1 rs1695 and the CYP1A1 rs1048943 genotypes affect the risk of NHL in Korea.	0.019207698	2009	CYP1A1	15	74720644	T	G,C,A
rs1048943	19899130	2950	GSTP1	umls:C0024305	BeFree	Our data provide evidence that the GSTP1 rs1695 and the CYP1A1 rs1048943 genotypes affect the risk of NHL in Korea.	0.023289257	2009	CYP1A1	15	74720644	T	G,C,A
rs1049216	17071630	841	CASP8	umls:C0024305	BeFree	We investigated five single nucleotide polymorphisms in four key caspase genes, CASP3 [Ex8-280C>A (rs6948) and Ex8+567T>C (rs1049216)], CASP8 Ex14-271A>T (rs13113), CASP9 Ex5+32G>A (rs1052576) and CASP10 Ex3-171A>G (rs3900115) to determine whether they alter risk for non-Hodgkin lymphoma (NHL) in a population-based case-control study of women in Connecticut (461 cases and 535 controls).	0.00764398	2007	CASP3	4	184628935	A	G
rs1051266	15198953	6573	SLC19A1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.005005506	2004	SLC19A1	21	45537880	T	C
rs1051266	15198953	6470	SHMT1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.127915422	2004	SLC19A1	21	45537880	T	C
rs1052576	17071630	841	CASP8	umls:C0024305	BeFree	We investigated five single nucleotide polymorphisms in four key caspase genes, CASP3 [Ex8-280C>A (rs6948) and Ex8+567T>C (rs1049216)], CASP8 Ex14-271A>T (rs13113), CASP9 Ex5+32G>A (rs1052576) and CASP10 Ex3-171A>G (rs3900115) to determine whether they alter risk for non-Hodgkin lymphoma (NHL) in a population-based case-control study of women in Connecticut (461 cases and 535 controls).	0.00764398	2007	CASP9	1	15506048	T	C
rs10993994	24598796	54790	TET2	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000542884	2014	MSMB	10	46046326	A	G
rs10993994	24598796	4046	LSP1	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.002909916	2014	MSMB	10	46046326	A	G
rs10993994	24598796	4477	MSMB	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	MSMB	10	46046326	A	G
rs10993994	24598796	4439	MSH5	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	MSMB	10	46046326	A	G
rs10993994	24598796	7015	TERT	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	MSMB	10	46046326	A	G
rs1127717	23913011	10840	ALDH1L1	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	ALDH1L1;ALDH1L1-AS1	3	126107216	T	C
rs1127717	23913011	8932	MBD2	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.000271442	2013	ALDH1L1;ALDH1L1-AS1	3	126107216	T	C
rs1127717	23913011	4552	MTRR	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	ALDH1L1;ALDH1L1-AS1	3	126107216	T	C
rs1136410	20196871	142	PARP1	umls:C0024305	BeFree	PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.	0.005005506	2010	PARP1	1	226367601	A	G
rs114216685	NA	25788	RAD54B	umls:C0024305	CLINVAR	NA	0.12	NA	RAD54B	8	94391640	T	C
rs121908689	NA	8438	RAD54L	umls:C0024305	CLINVAR	NA	0.242367032	NA	RAD54L	1	46272758	T	A
rs121909775	NA	843	CASP10	umls:C0024305	CLINVAR	NA	0.369825446	NA	CASP10	2	201205929	C	A,T
rs121912659	NA	7157	TP53	umls:C0024305	CLINVAR	NA	0.132539865	NA	TP53	17	7673554	C	A
rs121913338	NA	673	BRAF	umls:C0024305	CLINVAR	NA	0.242367032	NA	BRAF	7	140753354	T	C,A
rs121913355	NA	673	BRAF	umls:C0024305	CLINVAR	NA	0.242367032	NA	BRAF	7	140781602	C	T,G,A
rs121913357	NA	673	BRAF	umls:C0024305	CLINVAR	NA	0.242367032	NA	BRAF	7	140781603	C	T,G,A
rs121913499	20946881	3417	IDH1	umls:C0024305	BeFree	Except for one non-Hodgkin lymphoma (NHL) patient harboring IDH1 mutation p.R132C, all IDH1 and IDH2 missense mutations were observed in patients with AML.	0.002638474	2010	IDH1	2	208248389	G	T,A
rs12203592	19396635	3056	HCL1	umls:C0024305	BeFree	Analysis of joint effects between eye and hair color with the IRF4 rs12203592 SNP did not reveal statistically significant p-interactions although NHL risk did decline with lighter hair color and presence of the variant IRF4 rs12203592 allele, compared to those without a variant allele and with black/brown hair color.	0.000271442	2009	IRF4	6	396321	C	T
rs12211228	19390683	2194	FASN	umls:C0024305	BeFree	Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-trend = 0.0024), IRF4 rs12211228 (p-trend = 0.0026), TNFSF13B rs2582869 (p-trend = 0.0055), TANK rs1921310 (p-trend = 0.0025), TNFSF7 rs16994592 (p-trend = 0.0024), and TNFRSF13C rs6002551 (p-trend = 0.0074).	0.000542884	2009	IRF4	6	408833	G	C
rs12711521	23055202	4155	MBP	umls:C0024305	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.000271442	2013	MASP2	1	11030859	C	A
rs12711521	23055202	10747	MASP2	umls:C0024305	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.002638474	2013	MASP2	1	11030859	C	A
rs13113	17071630	841	CASP8	umls:C0024305	BeFree	We investigated five single nucleotide polymorphisms in four key caspase genes, CASP3 [Ex8-280C>A (rs6948) and Ex8+567T>C (rs1049216)], CASP8 Ex14-271A>T (rs13113), CASP9 Ex5+32G>A (rs1052576) and CASP10 Ex3-171A>G (rs3900115) to determine whether they alter risk for non-Hodgkin lymphoma (NHL) in a population-based case-control study of women in Connecticut (461 cases and 535 controls).	0.00764398	2007	CASP8	2	201287439	T	A
rs13178127	20813000	7518	XRCC4	umls:C0024305	BeFree	Five SNPs (BLM rs441399, RAD50 rs2237060, FAM82A2 rs2304583, ERCC3 rs4150506, and XRCC4 rs13178127) were particularly noteworthy because their gene regions were significantly associated with NHL or NHL subtypes (minP ≤ 0·05), or because of high level of statistical significance (P ≤ 0·005) and consistent findings across the three studies.	0.002638474	2010	XRCC4	5	83293613	A	G
rs13181	25422223	2068	ERCC2	umls:C0024305	BeFree	Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.	0.012649486	2015	ERCC2;KLC3	19	45351661	T	A,G
rs13181	23619945	672	BRCA1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.005276948	2013	ERCC2;KLC3	19	45351661	T	A,G
rs13181	23619945	7515	XRCC1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00764398	2013	ERCC2;KLC3	19	45351661	T	A,G
rs13181	23619945	2068	ERCC2	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.012649486	2013	ERCC2;KLC3	19	45351661	T	A,G
rs13181	23619945	7486	WRN	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00554839	2013	ERCC2;KLC3	19	45351661	T	A,G
rs1346044	25178586	7486	WRN	umls:C0024305	BeFree	In addition, a significant interaction with risk of overall NHL was observed between WRN rs1346044 and hair dye use before 1980 (p(interaction) = 0.032).	0.00554839	2014	WRN;LOC105379359	8	31167138	T	C
rs13706	19101572	990	CDC6	umls:C0024305	BeFree	Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.	0.002638474	2009	CDC6	17	40300899	G	A,C
rs1494555	20952689	7124	TNF	umls:C0024305	BeFree	A significant interaction with BMI was only observed for IFNGR2 (rs9808753 P(forinteraction) = .034) and IL7R (rs1494555 P(forinteraction) = .016) for NHL overall; IL7R (rs1494555 P(forinteraction) = .016) and TNF (1799724 P(forinteraction) = .031) for B-cell lymphoma; and IL5 (rs2069812 P(forinteraction) = .034) for T-cell lymphoma.	0.049749941	2011	IL7R	5	35871088	G	A
rs161870	23913011	10840	ALDH1L1	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	MTRR	5	7878079	T	C
rs161870	23913011	8932	MBD2	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.000271442	2013	MTRR	5	7878079	T	C
rs161870	23913011	4552	MTRR	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	MTRR	5	7878079	T	C
rs1695	22734843	2944	GSTM1	umls:C0024305	BeFree	Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in Hodgkin and non-Hodgkin lymphoma risk: a Human Genome Epidemiology (HuGE) review.	0.02073666	2013	GSTP1	11	67585218	A	G
rs1695	19899130	2950	GSTP1	umls:C0024305	BeFree	Our data provide evidence that the GSTP1 rs1695 and the CYP1A1 rs1048943 genotypes affect the risk of NHL in Korea.	0.023289257	2009	GSTP1	11	67585218	A	G
rs1695	22734843	2952	GSTT1	umls:C0024305	BeFree	Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in Hodgkin and non-Hodgkin lymphoma risk: a Human Genome Epidemiology (HuGE) review.	0.017469426	2013	GSTP1	11	67585218	A	G
rs1695	19899130	1543	CYP1A1	umls:C0024305	BeFree	Our data provide evidence that the GSTP1 rs1695 and the CYP1A1 rs1048943 genotypes affect the risk of NHL in Korea.	0.019207698	2009	GSTP1	11	67585218	A	G
rs1695	22734843	2950	GSTP1	umls:C0024305	BeFree	Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in Hodgkin and non-Hodgkin lymphoma risk: a Human Genome Epidemiology (HuGE) review.	0.023289257	2013	GSTP1	11	67585218	A	G
rs16994592	19390683	2194	FASN	umls:C0024305	BeFree	Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-trend = 0.0024), IRF4 rs12211228 (p-trend = 0.0026), TNFSF13B rs2582869 (p-trend = 0.0055), TANK rs1921310 (p-trend = 0.0025), TNFSF7 rs16994592 (p-trend = 0.0024), and TNFRSF13C rs6002551 (p-trend = 0.0074).	0.000542884	2009	CD70	19	6586487	T	C
rs1785882	19414860	842	CASP9	umls:C0024305	BeFree	SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) (CG) = 1.21; OR(CC) = 2.13; P trend = .011); CASP9 rs4661636 (OR(CT) = 0.89; OR(TT) = 0.77; P trend = .011); and CASP1 rs1785882 (OR(AT) = 1.12; OR(AA) = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies.	0.00764398	2009	NA	11	105052348	A	T
rs1785882	19414860	834	CASP1	umls:C0024305	BeFree	SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) (CG) = 1.21; OR(CC) = 2.13; P trend = .011); CASP9 rs4661636 (OR(CT) = 0.89; OR(TT) = 0.77; P trend = .011); and CASP1 rs1785882 (OR(AT) = 1.12; OR(AA) = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies.	0.005005506	2009	NA	11	105052348	A	T
rs1799724	17018637	7124	TNF	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.049749941	2006	LTA;TNF	6	31574705	C	T
rs1799724	17018637	4049	LTA	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.025927731	2006	LTA;TNF	6	31574705	C	T
rs1799782	23619945	2068	ERCC2	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.012649486	2013	XRCC1	19	43553422	G	A
rs1799782	23619945	672	BRCA1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.005276948	2013	XRCC1	19	43553422	G	A
rs1799782	23619945	7486	WRN	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00554839	2013	XRCC1	19	43553422	G	A
rs1799782	23619945	7515	XRCC1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00764398	2013	XRCC1	19	43553422	G	A
rs1799793	25422223	2068	ERCC2	umls:C0024305	BeFree	Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.	0.012649486	2015	ERCC2	19	45364001	C	T
rs1800629	17018637	4049	LTA	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.025927731	2006	TNF	6	31575254	G	A
rs1800629	19654554	4049	LTA	umls:C0024305	BeFree	Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of non-Hodgkin lymphoma (NHL) in individuals uninfected with HIV-1.	0.025927731	2009	TNF	6	31575254	G	A
rs1800629	20087644	7124	TNF	umls:C0024305	BeFree	TNF rs1800629 was associated with risk of NHL (OR 1.53, 95% confidence interval, CI, 1.06-2.19 for minor allele homozygosity), T-cell lymphoma (OR 2.54, CI 1.27-5.09) and mantle cell lymphoma (OR 2.84, CI 1.38-5.87).	0.049749941	2010	TNF	6	31575254	G	A
rs1800629	19654554	7124	TNF	umls:C0024305	BeFree	Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of non-Hodgkin lymphoma (NHL) in individuals uninfected with HIV-1.	0.049749941	2009	TNF	6	31575254	G	A
rs1800629	17018637	7124	TNF	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.049749941	2006	TNF	6	31575254	G	A
rs1800795	25564959	3569	IL6	umls:C0024305	BeFree	Given the importance of understanding the genetic variations involved in the pathogenesis of non-Hodgkin's lymphoma (NHL), this pilot study was designed to investigate the impact of CD38 (184C/G; rs6449182) and IL-6 (-174 G/C; rs1800795) gene polymorphism on susceptibility of Egyptians to diffuse large B cell lymphoma (DLBCL); major types of NHL.	0.016002596	2016	IL6;LOC541472	7	22727026	C	G
rs1800890	19573080	3586	IL10	umls:C0024305	BeFree	We confirmed previous studies showing a polymorphism in the IL10 promoter (rs1800890/-3575T>A) to be associated with non-Hodgkin lymphoma, as this allele was found to be associated with both CLL and WM.	0.048378919	2009	IL10	1	206776020	A	T
rs1801181	23913011	6470	SHMT1	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.127915422	2013	CBS	21	43060506	G	A
rs1801181	23913011	102724560	LOC102724560	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.000814326	2013	CBS	21	43060506	G	A
rs1801195	23619945	7486	WRN	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00554839	2013	WRN	8	31141764	G	T
rs1801195	23619945	2068	ERCC2	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.012649486	2013	WRN	8	31141764	G	T
rs1801195	23619945	672	BRCA1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.005276948	2013	WRN	8	31141764	G	T
rs1801195	23619945	7515	XRCC1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00764398	2013	WRN	8	31141764	G	T
rs1801274	17018637	2209	FCGR1A	umls:C0024305	BeFree	A functional nonsynonymous SNP in the innate immune gene Fc gamma receptor 2A (FCGR2A; rs1801274) was also associated with non-Hodgkin lymphoma; AG and AA genotypes were associated with a 1.26-fold (95% CI, 1.01-1.56) and 1.41-fold (95% CI, 1.10-1.81) increased risk, respectively (P(trend) = 0.006).	0.000542884	2006	FCGR2A	1	161509955	A	G
rs1801274	17018637	2212	FCGR2A	umls:C0024305	BeFree	A functional nonsynonymous SNP in the innate immune gene Fc gamma receptor 2A (FCGR2A; rs1801274) was also associated with non-Hodgkin lymphoma; AG and AA genotypes were associated with a 1.26-fold (95% CI, 1.01-1.56) and 1.41-fold (95% CI, 1.10-1.81) increased risk, respectively (P(trend) = 0.006).	0.01036833	2006	FCGR2A	1	161509955	A	G
rs1805087	15198953	6470	SHMT1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.127915422	2004	MTR	1	236885200	A	G
rs1805087	15198953	6573	SLC19A1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.005005506	2004	MTR	1	236885200	A	G
rs1921310	19390683	2194	FASN	umls:C0024305	BeFree	Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-trend = 0.0024), IRF4 rs12211228 (p-trend = 0.0026), TNFSF13B rs2582869 (p-trend = 0.0055), TANK rs1921310 (p-trend = 0.0025), TNFSF7 rs16994592 (p-trend = 0.0024), and TNFRSF13C rs6002551 (p-trend = 0.0074).	0.000542884	2009	TANK	2	161192690	A	G
rs1979276	23913011	6470	SHMT1	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.127915422	2013	SHMT1	17	18328684	G	A
rs1979276	23913011	102724560	LOC102724560	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.000814326	2013	SHMT1	17	18328684	G	A
rs1979277	15198953	6470	SHMT1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.127915422	2004	SHMT1	17	18328782	G	A
rs1979277	15198953	6573	SLC19A1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.005005506	2004	SHMT1	17	18328782	G	A
rs1979277	23913011	102724560	LOC102724560	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.000814326	2013	SHMT1	17	18328782	G	A
rs1979277	23913011	6470	SHMT1	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.127915422	2013	SHMT1	17	18328782	G	A
rs201765376	15198953	6573	SLC19A1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.005005506	2004	MTR	1	236838504	C	T
rs201765376	15198953	6470	SHMT1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.127915422	2004	MTR	1	236838504	C	T
rs20541	19533685	7412	VCAM1	umls:C0024305	BeFree	Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).	0.002638474	2009	IL13	5	132660272	A	G
rs20541	19533685	3596	IL13	umls:C0024305	BeFree	Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).	0.000814326	2009	IL13	5	132660272	A	G
rs2069812	20952689	7124	TNF	umls:C0024305	BeFree	A significant interaction with BMI was only observed for IFNGR2 (rs9808753 P(forinteraction) = .034) and IL7R (rs1494555 P(forinteraction) = .016) for NHL overall; IL7R (rs1494555 P(forinteraction) = .016) and TNF (1799724 P(forinteraction) = .031) for B-cell lymphoma; and IL5 (rs2069812 P(forinteraction) = .034) for T-cell lymphoma.	0.049749941	2011	IL5	5	132544224	A	G
rs2237060	20813000	7518	XRCC4	umls:C0024305	BeFree	Five SNPs (BLM rs441399, RAD50 rs2237060, FAM82A2 rs2304583, ERCC3 rs4150506, and XRCC4 rs13178127) were particularly noteworthy because their gene regions were significantly associated with NHL or NHL subtypes (minP ≤ 0·05), or because of high level of statistical significance (P ≤ 0·005) and consistent findings across the three studies.	0.002638474	2010	RAD50;LOC101927761	5	132635193	T	G
rs2239704	17018637	4049	LTA	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.025927731	2006	LTA;LOC100287329	6	31572364	A	C
rs2239704	17018637	7124	TNF	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.049749941	2006	LTA;LOC100287329	6	31572364	A	C
rs2297518	16543247	4843	NOS2	umls:C0024305	BeFree	Specifically, for nitric oxide synthase (NOS2A Ser608Leu, rs2297518) Leu/Leu homozygotes, there was a 2-fold risk increase for NHL (OR=2.2, 95% CI=1.1-4.4) (referent=Ser/Ser and Ser/Leu).	0.005276948	2006	NOS2	17	27769571	G	A
rs2304583	20813000	7518	XRCC4	umls:C0024305	BeFree	Five SNPs (BLM rs441399, RAD50 rs2237060, FAM82A2 rs2304583, ERCC3 rs4150506, and XRCC4 rs13178127) were particularly noteworthy because their gene regions were significantly associated with NHL or NHL subtypes (minP ≤ 0·05), or because of high level of statistical significance (P ≤ 0·005) and consistent findings across the three studies.	0.002638474	2010	RMDN3	15	40739940	A	G
rs2305230	23913011	6470	SHMT1	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.127915422	2013	ALDH1L1	3	126137852	C	A
rs2305230	23913011	102724560	LOC102724560	umls:C0024305	BeFree	A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.	0.000814326	2013	ALDH1L1	3	126137852	C	A
rs234706	23913011	10840	ALDH1L1	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	CBS	21	43065240	G	A
rs234706	23913011	8932	MBD2	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.000271442	2013	CBS	21	43065240	G	A
rs234706	23913011	4552	MTRR	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	CBS	21	43065240	G	A
rs2582869	19390683	2194	FASN	umls:C0024305	BeFree	Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-trend = 0.0024), IRF4 rs12211228 (p-trend = 0.0026), TNFSF13B rs2582869 (p-trend = 0.0055), TANK rs1921310 (p-trend = 0.0025), TNFSF7 rs16994592 (p-trend = 0.0024), and TNFRSF13C rs6002551 (p-trend = 0.0074).	0.000542884	2009	LOC105370354	13	108259797	A	G
rs2647012	23455380	3662	IRF4	umls:C0024305	BeFree	Only two variants (rs872071 in IRF4 and rs2647012 in HLA class II) were significantly associated with NHL risk in Chinese, with the ORs of 1.20 (95% CI, 1.05-1.38; P = 0.009) and 1.20 (95% CI, 1.03-1.39; P = 0.018) for per allele of rs872071 and rs2647012, respectively, calculated using an additive model.	0.001085767	2013	NA	6	32696681	T	C
rs2855429	21148756	7918	GPANK1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	COL11A2	6	33190412	A	C
rs2855429	21148756	199	AIF1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.002638474	2011	COL11A2	6	33190412	A	C
rs2855429	21148756	6257	RXRB	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	COL11A2	6	33190412	A	C
rs2855429	21148756	6015	RING1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	COL11A2	6	33190412	A	C
rs2857597	21148756	7918	GPANK1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	AIF1	6	31617223	T	A
rs2857597	21148756	6257	RXRB	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	AIF1	6	31617223	T	A
rs2857597	21148756	6015	RING1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	AIF1	6	31617223	T	A
rs2857597	21148756	199	AIF1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.002638474	2011	AIF1	6	31617223	T	A
rs28933375	NA	5551	PRF1	umls:C0024305	CLINVAR	NA	0.24	NA	PRF1	10	70598966	T	C
rs28936699	12010812	843	CASP10	umls:C0024305	UNIPROT	Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas.	0.369825446	2002	CASP10	2	201209388	C	T
rs28936699	NA	843	CASP10	umls:C0024305	CLINVAR	NA	0.369825446	NA	CASP10	2	201209388	C	T
rs3115667	21148756	7918	GPANK1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	NA	6	31675622	T	C
rs3115667	21148756	6257	RXRB	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	NA	6	31675622	T	C
rs3115667	21148756	199	AIF1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.002638474	2011	NA	6	31675622	T	C
rs3115667	21148756	6015	RING1	umls:C0024305	BeFree	Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05).	0.000271442	2011	NA	6	31675622	T	C
rs3131379	24598796	4477	MSMB	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	MSH5;MSH5-SAPCD1	6	31753256	G	A
rs3131379	24598796	7015	TERT	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	MSH5;MSH5-SAPCD1	6	31753256	G	A
rs3131379	24598796	54790	TET2	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000542884	2014	MSH5;MSH5-SAPCD1	6	31753256	G	A
rs3131379	24598796	4439	MSH5	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	MSH5;MSH5-SAPCD1	6	31753256	G	A
rs3131379	24598796	4046	LSP1	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.002909916	2014	MSH5;MSH5-SAPCD1	6	31753256	G	A
rs361525	17018637	4049	LTA	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.025927731	2006	TNF	6	31575324	G	A
rs361525	17018637	7124	TNF	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.049749941	2006	TNF	6	31575324	G	A
rs3813729	22170086	51279	C1RL	umls:C0024305	BeFree	A SNP-based analysis showed that a C>T base substitution for C1RL rs3813729 (odds ratio (OR)(CT) = 0.60, 95% confidence interval (CI) = 0.42-0.87, P(trend) = 0.0062) was associated with a decreased risk of overall NHL, as well as for DLBCL (OR(CT) = 0.39, 95% CI = 0.20-0.73; P(trend) = 0.0034).	0.002638474	2012	NA	NA	NA	NA	NA
rs3817198	24598796	4046	LSP1	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.002909916	2014	LSP1	11	1887776	T	C
rs3817198	24598796	7015	TERT	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	LSP1	11	1887776	T	C
rs3817198	24598796	4477	MSMB	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	LSP1	11	1887776	T	C
rs3817198	24598796	54790	TET2	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000542884	2014	LSP1	11	1887776	T	C
rs3817198	24598796	4439	MSH5	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	LSP1	11	1887776	T	C
rs386514057	15198953	6573	SLC19A1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.005005506	2004	NA	NA	NA	NA	NA
rs386514057	15198953	6470	SHMT1	umls:C0024305	BeFree	The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.	0.127915422	2004	NA	NA	NA	NA	NA
rs3900115	17071630	841	CASP8	umls:C0024305	BeFree	We investigated five single nucleotide polymorphisms in four key caspase genes, CASP3 [Ex8-280C>A (rs6948) and Ex8+567T>C (rs1049216)], CASP8 Ex14-271A>T (rs13113), CASP9 Ex5+32G>A (rs1052576) and CASP10 Ex3-171A>G (rs3900115) to determine whether they alter risk for non-Hodgkin lymphoma (NHL) in a population-based case-control study of women in Connecticut (461 cases and 535 controls).	0.00764398	2007	CASP10	2	201185954	A	G
rs397507444	25146845	4524	MTHFR	umls:C0024305	BeFree	Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis.	0.136916611	2014	MTHFR	1	11794407	T	G
rs397507444	18432505	4524	MTHFR	umls:C0024305	BeFree	This is the first reported case of intracardiac thrombosis with MTHFR A1298C and factor XIII V34L mutations together with granulomatous reaction in non-Hodgkin lymphoma.	0.136916611	2008	MTHFR	1	11794407	T	G
rs397507444	19391036	4524	MTHFR	umls:C0024305	BeFree	Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.	0.136916611	2009	MTHFR	1	11794407	T	G
rs398122800	NA	843	CASP10	umls:C0024305	CLINVAR	NA	0.369825446	NA	CASP10	2	201209189	-	A
rs401681	24598796	54790	TET2	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000542884	2014	CLPTM1L	5	1321972	C	T
rs401681	24598796	4477	MSMB	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	CLPTM1L	5	1321972	C	T
rs401681	24598796	4046	LSP1	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.002909916	2014	CLPTM1L	5	1321972	C	T
rs401681	24598796	4439	MSH5	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	CLPTM1L	5	1321972	C	T
rs401681	24598796	7015	TERT	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	CLPTM1L	5	1321972	C	T
rs4150506	20813000	7518	XRCC4	umls:C0024305	BeFree	Five SNPs (BLM rs441399, RAD50 rs2237060, FAM82A2 rs2304583, ERCC3 rs4150506, and XRCC4 rs13178127) were particularly noteworthy because their gene regions were significantly associated with NHL or NHL subtypes (minP ≤ 0·05), or because of high level of statistical significance (P ≤ 0·005) and consistent findings across the three studies.	0.002638474	2010	ERCC3	2	127262970	G	A
rs4245739	25203442	7157	TP53	umls:C0024305	BeFree	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.	0.132539865	2014	MDM4	1	204549714	C	A
rs4245739	25203442	4194	MDM4	umls:C0024305	BeFree	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.	0.000271442	2014	MDM4	1	204549714	C	A
rs441399	20813000	7518	XRCC4	umls:C0024305	BeFree	Five SNPs (BLM rs441399, RAD50 rs2237060, FAM82A2 rs2304583, ERCC3 rs4150506, and XRCC4 rs13178127) were particularly noteworthy because their gene regions were significantly associated with NHL or NHL subtypes (minP ≤ 0·05), or because of high level of statistical significance (P ≤ 0·005) and consistent findings across the three studies.	0.002638474	2010	NA	15	90822992	G	A
rs4661636	19414860	834	CASP1	umls:C0024305	BeFree	SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) (CG) = 1.21; OR(CC) = 2.13; P trend = .011); CASP9 rs4661636 (OR(CT) = 0.89; OR(TT) = 0.77; P trend = .011); and CASP1 rs1785882 (OR(AT) = 1.12; OR(AA) = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies.	0.005005506	2009	CASP9	1	15496566	C	T
rs4661636	19414860	842	CASP9	umls:C0024305	BeFree	SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) (CG) = 1.21; OR(CC) = 2.13; P trend = .011); CASP9 rs4661636 (OR(CT) = 0.89; OR(TT) = 0.77; P trend = .011); and CASP1 rs1785882 (OR(AT) = 1.12; OR(AA) = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies.	0.00764398	2009	CASP9	1	15496566	C	T
rs4934436	19390683	2194	FASN	umls:C0024305	BeFree	Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-trend = 0.0024), IRF4 rs12211228 (p-trend = 0.0026), TNFSF13B rs2582869 (p-trend = 0.0055), TANK rs1921310 (p-trend = 0.0025), TNFSF7 rs16994592 (p-trend = 0.0024), and TNFRSF13C rs6002551 (p-trend = 0.0074).	0.000542884	2009	NA	10	89023563	C	T
rs4975616	24598796	7015	TERT	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	NA	5	1315545	G	A
rs4975616	24598796	4477	MSMB	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	NA	5	1315545	G	A
rs4975616	24598796	4439	MSH5	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	NA	5	1315545	G	A
rs4975616	24598796	54790	TET2	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000542884	2014	NA	5	1315545	G	A
rs4975616	24598796	4046	LSP1	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.002909916	2014	NA	5	1315545	G	A
rs5743836	21866115	54106	TLR9	umls:C0024305	BeFree	The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma.	0.000271442	2012	TLR9	3	52226766	A	G
rs6002551	19390683	2194	FASN	umls:C0024305	BeFree	Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-trend = 0.0024), IRF4 rs12211228 (p-trend = 0.0026), TNFSF13B rs2582869 (p-trend = 0.0055), TANK rs1921310 (p-trend = 0.0025), TNFSF7 rs16994592 (p-trend = 0.0024), and TNFRSF13C rs6002551 (p-trend = 0.0074).	0.000542884	2009	CENPM	22	41942148	G	A
rs603097	23913011	8932	MBD2	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.000271442	2013	MBD2	18	54226736	G	A
rs603097	23913011	10840	ALDH1L1	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	MBD2	18	54226736	G	A
rs603097	23913011	4552	MTRR	umls:C0024305	BeFree	A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).	0.00554839	2013	MBD2	18	54226736	G	A
rs63750042	17601929	4436	MSH2	umls:C0024305	BeFree	We report homozygous truncating mutations in the mismatch repair gene MSH2 (226C-->T; Q76X) in three siblings who each developed T-cell NHL in early childhood.	0.01372144	2007	MSH2	2	47408415	C	G,T
rs6449182	25564959	3569	IL6	umls:C0024305	BeFree	Given the importance of understanding the genetic variations involved in the pathogenesis of non-Hodgkin's lymphoma (NHL), this pilot study was designed to investigate the impact of CD38 (184C/G; rs6449182) and IL-6 (-174 G/C; rs1800795) gene polymorphism on susceptibility of Egyptians to diffuse large B cell lymphoma (DLBCL); major types of NHL.	0.016002596	2016	CD38	4	15778830	C	G
rs6736233	19414860	834	CASP1	umls:C0024305	BeFree	SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) (CG) = 1.21; OR(CC) = 2.13; P trend = .011); CASP9 rs4661636 (OR(CT) = 0.89; OR(TT) = 0.77; P trend = .011); and CASP1 rs1785882 (OR(AT) = 1.12; OR(AA) = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies.	0.005005506	2009	CASP8	2	201254251	G	C
rs6736233	19414860	842	CASP9	umls:C0024305	BeFree	SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) (CG) = 1.21; OR(CC) = 2.13; P trend = .011); CASP9 rs4661636 (OR(CT) = 0.89; OR(TT) = 0.77; P trend = .011); and CASP1 rs1785882 (OR(AT) = 1.12; OR(AA) = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies.	0.00764398	2009	CASP8	2	201254251	G	C
rs6948	17071630	841	CASP8	umls:C0024305	BeFree	We investigated five single nucleotide polymorphisms in four key caspase genes, CASP3 [Ex8-280C>A (rs6948) and Ex8+567T>C (rs1049216)], CASP8 Ex14-271A>T (rs13113), CASP9 Ex5+32G>A (rs1052576) and CASP10 Ex3-171A>G (rs3900115) to determine whether they alter risk for non-Hodgkin lymphoma (NHL) in a population-based case-control study of women in Connecticut (461 cases and 535 controls).	0.00764398	2007	CASP3	4	184627976	G	T
rs7679673	24598796	54790	TET2	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000542884	2014	NA	4	105140377	C	A
rs7679673	24598796	4439	MSH5	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	NA	4	105140377	C	A
rs7679673	24598796	7015	TERT	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	NA	4	105140377	C	A
rs7679673	24598796	4046	LSP1	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.002909916	2014	NA	4	105140377	C	A
rs7679673	24598796	4477	MSMB	umls:C0024305	BeFree	In the pleiotropy analysis, six risk variants for other cancers were associated with NHL risk, including variants for lung (rs401681 in TERT: OR per C allele=0.89, p=3.7 × E-03; rs4975616 in TERT: OR per A allele=0.90, p=0.01; rs3131379 in MSH5: OR per T allele=1.16, p=0.03), prostate (rs7679673 in TET2: OR per C allele=0.89, p=5.7 × E-03; rs10993994 in MSMB: OR per T allele=1.09, p=0.04), and breast (rs3817198 in LSP1: OR per C allele=1.12, p=0.01) cancers, but none of these associations remained significant after multiple test correction.	0.000271442	2014	NA	4	105140377	C	A
rs799917	23619945	7515	XRCC1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00764398	2013	BRCA1	17	43092919	G	T,C,A
rs799917	23619945	672	BRCA1	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.005276948	2013	BRCA1	17	43092919	G	T,C,A
rs799917	23619945	2068	ERCC2	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.012649486	2013	BRCA1	17	43092919	G	T,C,A
rs799917	23619945	7486	WRN	umls:C0024305	BeFree	Compared to those with BMI <25, women with BMI ≥25 had significantly increased risk of NHL among women who carried BRCA1 (rs799917) CT/TT, ERCC2 (rs13181) AA, XRCC1 (rs1799782) CC, and WRN (rs1801195) GG genotypes, but no increase in NHL risk among women who carried BRCA1 CC, ERCC2 AC/CC, XRCC1 CT/TT, and WRN GT/TT genotypes.	0.00554839	2013	BRCA1	17	43092919	G	T,C,A
rs8094402	23055202	4155	MBP	umls:C0024305	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.000271442	2013	MBP	18	76995493	A	G
rs8094402	23055202	10747	MASP2	umls:C0024305	BeFree	A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042).	0.002638474	2013	MBP	18	76995493	A	G
rs872071	23455380	3662	IRF4	umls:C0024305	BeFree	Only two variants (rs872071 in IRF4 and rs2647012 in HLA class II) were significantly associated with NHL risk in Chinese, with the ORs of 1.20 (95% CI, 1.05-1.38; P = 0.009) and 1.20 (95% CI, 1.03-1.39; P = 0.018) for per allele of rs872071 and rs2647012, respectively, calculated using an additive model.	0.001085767	2013	IRF4	6	411064	A	G
rs909253	17018637	7124	TNF	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.049749941	2006	LTA;LOC100287329	6	31572536	A	G
rs909253	19654554	7124	TNF	umls:C0024305	BeFree	Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of non-Hodgkin lymphoma (NHL) in individuals uninfected with HIV-1.	0.049749941	2009	LTA;LOC100287329	6	31572536	A	G
rs909253	17018637	4049	LTA	umls:C0024305	BeFree	A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007).	0.025927731	2006	LTA;LOC100287329	6	31572536	A	G
rs909253	19654554	4049	LTA	umls:C0024305	BeFree	Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of non-Hodgkin lymphoma (NHL) in individuals uninfected with HIV-1.	0.025927731	2009	LTA;LOC100287329	6	31572536	A	G
rs9808753	20952689	7124	TNF	umls:C0024305	BeFree	A significant interaction with BMI was only observed for IFNGR2 (rs9808753 P(forinteraction) = .034) and IL7R (rs1494555 P(forinteraction) = .016) for NHL overall; IL7R (rs1494555 P(forinteraction) = .016) and TNF (1799724 P(forinteraction) = .031) for B-cell lymphoma; and IL5 (rs2069812 P(forinteraction) = .034) for T-cell lymphoma.	0.049749941	2011	IFNGR2	21	33415005	A	G

GWASdb Annotation(Total Genotypes:4)
Chr	Pos	SNP_Id	RefGene	EnsemblGene	ENCODE_Factor	ENCODE_TFBS	Chromosome_interaction	GTEx_eQTL	SNP_TFBS_affinity_GWAS3D	SNP_miRNA_target_affinity_PolymiRTS	SNP_splicing_effect_Skippy	SNP_splicing_effect_MutPred_Splice	SNP_ns_protein_effect_dbNSFP	SNP_syn_effect_Silva	SNP_phosphorylation_effect_PhosSNP	PhastCons_score	PhyloP_score	GERP++_RS	Segway_state	Ancestral_allele	ESP_AF	ESP_AFR	ESP_AFR	ESP_EUR	TG_ASN	TG_AMR	TG_AFR	TG_EUR	Type	Consequence	bStatistic	EncH3K27Ac	EncH3K4Me1	EncH3K4Me3	EncNucleo	OMIM	Clinvar
20	62297802	rs6011002	NM_016434,RTEL1	NM_032957,RTEL1	NR_037882,RTEL1-TNFRSF6B	ENST00000318100,ENSG00000026036	ENST00000370018,ENSG00000026036	ENST00000508582,ENSG00000026036	ENST00000360203,ENSG00000026036	ENST00000356810,ENSG00000026036	ENST00000492259,ENSG00000026036	ENST00000370006,ENSG00000026036	ENST00000342852,ENSG00000026036	ENST00000482936,ENSG00000026036	ENST00000463361,ENSG00000026036	NA	NA	chr20,62290001,62300000,chr20,62310001,62320000,26,Hi-C	chr20,62290001,62300000,chr20,62190001,62200000,28,Hi-C	chr20,62290001,62300000,chr20,62480001,62490000,4,Hi-C	chr20,62290001,62300000,chr9,102010001,102020000,5,Hi-C	chr20,62290001,62300000,chr20,61710001,61720000,5,Hi-C	chr20,62290001,62300000,chr1,205110001,205120000,5,Hi-C	chr20,62290001,62300000,chr20,62310001,62320000,7,Hi-C	chr20,62290001,62300000,chr20,62320001,62330000,7,Hi-C	chr20,62290001,62300000,chr20,62140001,62150000,9,Hi-C	NA	LM23,1.5964	LM44,2.5795	LM73,5.8525	LM146,1.4055	LM159,2.9019	NA	NA	NA	NA	NA
20	62309839	rs6010620	NM_016434,RTEL1	NM_032957,RTEL1	NR_037882,RTEL1-TNFRSF6B	ENST00000318100,ENSG00000026036	ENST00000370018,ENSG00000026036	ENST00000508582,ENSG00000026036	ENST00000360203,ENSG00000026036	ENST00000492259,ENSG00000026036	ENST00000370006,ENSG00000026036	ENST00000342852,ENSG00000026036	ENST00000482936,ENSG00000026036	MCV-1	TFP.EGR1	NA	chr20,62300001,62310000,chr20,62690001,62700000,32,Hi-C	chr20,62300001,62310000,chr22,29420001,29430000,5,Hi-C	chr20,62300001,62310000,chr20,62540001,62550000,6,Hi-C	NA	Aft1-primary,7.9057	Asg1-DBD-primary,1.7781	Cbf1-primary,1.7474	Cbf1-primary,1.7474	Fhl1-DBD-primary,1.4045	NA	NA	NA	NA	NA	NA	0.002	0.766	0.876	TF2	G	NA
20	62312299	rs2297440	NM_016434,RTEL1	NM_032957,RTEL1	NR_037882,RTEL1-TNFRSF6B	ENST00000318100,ENSG00000026036	ENST00000370018,ENSG00000026036	ENST00000508582,ENSG00000026036	ENST00000360203,ENSG00000026036	ENST00000492259,ENSG00000026036	ENST00000370006,ENSG00000026036	ENST00000342852,ENSG00000026036	ENST00000482936,ENSG00000026036	NA	NA	chr20,62310001,62320000,chr20,62660001,62670000,25,Hi-C	chr20,62310001,62320000,chr20,62330001,62340000,26,Hi-C	chr20,62310001,62320000,chr20,62290001,62300000,26,Hi-C	chr20,62310001,62320000,chr20,60980001,60990000,35,Hi-C	chr20,62310001,62320000,chrX,88580001,88590000,64,Hi-C	chr20,62310001,62320000,chr17,870001,880000,6,Hi-C	chr20,62310001,62320000,chr4,39650001,39660000,6,Hi-C	chr20,62310001,62320000,chr20,62010001,62020000,15,Hi-C	chr20,62310001,62320000,chr20,62290001,62300000,7,Hi-C	chr20,62310001,62320000,chr22,50640001,50650000,7,Hi-C	chr20,62310001,62320000,chr12,84810001,84820000,7,Hi-C	NA	Aro80-primary,1.3536	Leu3-primary,8.4676	Mig3-primary,1.8306	Rhox11_1765,2.7383	Rhox11_2205,2.9881	NA	NA	NA	NA	NA
20	62318220	rs4809324	NM_016434,RTEL1	NM_032957,RTEL1	NR_037882,RTEL1-TNFRSF6B	ENST00000318100,ENSG00000026036	ENST00000370018,ENSG00000026036	ENST00000508582,ENSG00000026036	ENST00000360203,ENSG00000026036	ENST00000492259,ENSG00000026036	ENST00000370006,ENSG00000026036	ENST00000342852,ENSG00000026036	ENST00000482936,ENSG00000026036	ENST00000480273,ENSG00000026036	TFP.SMARCB1	TFP.STAT1	TFP.USF2	CHMM	TFP.SMC3	TFP.FOS	TFP.GTF2F1	TFP.E2F6	TFP.TAF1	TFP.MYC	TFP.STAT3	TFP.MAX	TFP.ELF1	TFP.E2F1	MCV-73	TFP.EGR1	NA	chr20,62310001,62320000,chr20,62660001,62670000,25,Hi-C	chr20,62310001,62320000,chr20,62330001,62340000,26,Hi-C	chr20,62310001,62320000,chr20,62290001,62300000,26,Hi-C	chr20,62310001,62320000,chr20,60980001,60990000,35,Hi-C	chr20,62310001,62320000,chrX,88580001,88590000,64,Hi-C	chr20,62310001,62320000,chr17,870001,880000,6,Hi-C

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:27)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0024305	allopurinol	D000493	315-30-0	lymphoma, non-hodgkin	MESH:D008228	therapeutic	2872506
C0024305	amifostine	D004999	20537-88-6	lymphoma, non-hodgkin	MESH:D008228	therapeutic	11335791
C0024305	bleomycin	D001761	11056-06-7	lymphoma, non-hodgkin	MESH:D008228	therapeutic	12172056
C0024305	busulfan	D002066	55-98-1	lymphoma, non-hodgkin	MESH:D008228	therapeutic	10955873
C0024305	chlorambucil	D002699	305-03-3	lymphoma, non-hodgkin	MESH:D008228	therapeutic	12512972
C0024305	cyclophosphamide	D003520	50-18-0	lymphoma, non-hodgkin	MESH:D008228	therapeutic	11911406
C0024305	calcitriol	D002117	32222-06-3	lymphoma, non-hodgkin	MESH:D008228	marker/mechanism	2261743
C0024305	epirubicin	D015251	56420-45-2	lymphoma, non-hodgkin	MESH:D008228	therapeutic	1617662
C0024305	leucovorin	D002955	1958/5/9	lymphoma, non-hodgkin	MESH:D008228	therapeutic	12172056
C0024305	gemcitabine	C056507	103882-84-4	lymphoma, non-hodgkin	MESH:D008228	therapeutic	16467107
C0024305	ifosfamide	D007069	3778-73-2	lymphoma, non-hodgkin	MESH:D008228	therapeutic	3132591
C0024305	lenalidomide	C467567	-	lymphoma, non-hodgkin	MESH:D008228	therapeutic	18217897
C0024305	lidocaine	D008012	137-58-6	lymphoma, non-hodgkin	MESH:D008228	marker/mechanism	8834551
C0024305	lindane	D001556	58-89-9	lymphoma, non-hodgkin	MESH:D008228	marker/mechanism	11700263
C0024305	melphalan	D008558	148-82-3	lymphoma, non-hodgkin	MESH:D008228	therapeutic	10955873
C0024305	meprobamate	D008620	57-53-4	lymphoma, non-hodgkin	MESH:D008228	marker/mechanism	8834551
C0024305	mesna	D015080	19767-45-4	lymphoma, non-hodgkin	MESH:D008228	therapeutic	11486401
C0024305	methotrexate	D008727	1959/5/2	lymphoma, non-hodgkin	MESH:D008228	therapeutic	12172056
C0024305	mitoxantrone	D008942	65271-80-9	lymphoma, non-hodgkin	MESH:D008228	therapeutic	1617662
C0024305	paclitaxel	D017239	-	lymphoma, non-hodgkin	MESH:D008228	therapeutic	10800167
C0024305	pegfilgrastim	C455861	-	lymphoma, non-hodgkin	MESH:D008228	therapeutic	14565651
C0024305	phenytoin	D010672	57-41-0	lymphoma, non-hodgkin	MESH:D008228	marker/mechanism	7336147
C0024305	teniposide	D013713	29767-20-2	lymphoma, non-hodgkin	MESH:D008228	therapeutic	4609765
C0024305	thalidomide	D013792	50-35-1	lymphoma, non-hodgkin	MESH:D008228	therapeutic	17408102
C0024305	thiotepa	D013852	52-24-4	lymphoma, non-hodgkin	MESH:D008228	therapeutic	10955873
C0024305	vincristine	D014750	-	lymphoma, non-hodgkin	MESH:D008228	therapeutic	12172056
C0024305	vindesine	D014751	53643-48-4	lymphoma, non-hodgkin	MESH:D008228	therapeutic	3327022

FDA approved drug and dosage information(Total Drugs:2)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D008228	calcijex	calcitriol	0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D008228	busulfex	busulfan	6MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes

FDA labeling changes(Total Drugs:2)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D008228	11/16/2001	calcijex	calcitriol	Management of hypocalcemia in patients undergoing chronic renal dialysis	The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75	Labeling	B	-	-	-	Abbott	02/16/2001	FALSE'
MESH:D008228	01/13/2003	busulfex	busulfan	Part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases	The population pharmacokinetic estimates of busulfan for clearance and volume of distribution were determined in an open-label, uncontrolled PK study in 24 pediatric patients 5 months to 16 years who received busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases Suggested dosing regimen	Labeling	B	-	-	-	Orphan Medical	12/3/2002	FALSE'